The study finds nearly 96% of patients deemed eligible for surgery survive in the first 48 hours.
Biopsies from the same patients before and after treatment reveal how a specific drug reprograms prostate tumors.
A clinical trial in head and neck cancer explored ways to improve clinical outcomes for patients. Although the trial failed, researchers found insight into new ways to address treatment resistance.
By using the lymphatic system as a storage reservoir, researchers found they could optimize drug concentrations to simultaneously target two molecular signaling pathways responsible for cancer growth.
Researchers identify a hormone from fat cells that reprogram the liver microenvironment and restrain tumor growth in mice
Molecular changes in nonalcoholic fatty liver disease could serve as potential therapeutic targets to halt the cells’ progression to liver cancer.
The technology developed at the University of Michigan continuously uses data from a single electrocardiogram lead.